Tamtam Try Tamtam free
H.B. Fuller logo

H.B. Fuller account plan

Adhesives, sealants, specialty chemicals

At a glance

H.B. Fuller is a NYSE-listed adhesives and sealants maker with FY2025 net revenue of $3,473.6 million and about 7,100 employees in 44 countries.

H.B. Fuller (NYSE: FUL), founded in 1887 in Minnesota, formulates, makes and sells adhesives, sealants and other specialty chemicals used in packaging, hygiene products, medical products, vehicles, electronics, solar, aerospace and construction. Products are mostly made in the region where they are sold, and no customer exceeds 10% of revenue. In fiscal 2025 (year ended November 29, 2025) net revenue was $3,473.6 million (-2.7%), adjusted EBITDA $620.7 million (17.9% of revenue) and net income attributable to the company $152.0 million. About 56% of revenue came from outside the U.S., and the company employed about 7,100 people in 44 countries. Celeste B. Mastin has been President and CEO since December 2022.

Business units

Strategic priorities

EBITDA margin above 20%
Investor Day goals are 5% constant-currency growth and a 20% EBITDA margin, which the CFO dated to 2028; the Q3 fiscal 2026 adjusted EBITDA margin was 19.9%.
Medical as a fourth segment
The pending Advanced Medical Solutions (AMS) acquisition grows medical adhesives from $68 million in revenue to approximately $370 million pro forma, about 10% of combined revenue, with EBITDA margins above 30% expected by 2030.
Quantum Leap footprint consolidation
Plants go from 82 at end-2024 to about 62 at end-2026 and below 60 by end-2027, with a goal of 55, targeting about $75 million of annualized conversion cost savings by end-2030.
Deleveraging after AMS
Leverage is expected at about 4x at the AMS close and is to return to the 2.5 to 3x target range within two years of closing; the CEO called deleveraging a very high priority.
Portfolio review
After the August 2026 portfolio review, management is assessing whether it is the best owner of every market segment and says a divestment is being taken seriously.
Pricing against raw material inflation
Price increases were announced in late March 2026; pricing exited Q3 fiscal 2026 at 7.6% as raw material prices stabilized at elevated levels after the Middle East supply disruption.

Latest results

In Q3 fiscal 2026 (three months ended August 29, 2026) net revenue rose 5.2% to $938.2 million, with pricing adding 7.4% while volume fell 3.0%; organic revenue grew 4.4%. Gross margin improved 120 bp to 33.2%, adjusted EBITDA rose 9.4% to $186.7 million (19.9% margin) and diluted EPS was $1.44 vs $1.22. Over nine months revenue was $2,659.3 million (+3.1%) and net income $168.0 million. Guidance for FY2026, excluding AMS, is adjusted EBITDA of $655 to $670 million, adjusted EPS of $4.70 to $4.85 and operating cash flow of $300 to $325 million.

Investments and deals

Advanced Medical Solutions acquisition
Recommended cash offer agreed June 25, 2026 at 285 pence per share, an enterprise value of about GBP 715 million; shareholders approved on August 12, 2026 and closing is expected by the end of calendar 2026. Expected run-rate synergies are about $55 million.
European medical adhesives base
GEM S.r.l. (Italy) and Medifill (Ireland) were bought in 2025 for about $196,990 thousand to establish a European headquarters for Medical Adhesives Technologies.
Fastener locking and precoating bolt-ons
ND Industries Taiwan (February 2025), ND Industries Turkey (November 2025, about $7,902 thousand) and Dongguan Nako Technology (August 2026, CNY 70,000 thousand) were added to Engineering Adhesives.
Footprint restructuring and capex
A footprint optimization programme approved in Q4 2025 is expected to cost $45.0 to $50.0 million through fiscal 2028; Quantum Leap needs $150 million of capital over its life. FY2025 capex was $142.3 million, with about $160.0 million expected in 2026.
Project ONE ERP
The global SAP programme, costing $300 to $320 million in total, now runs 97% of revenue on one SAP instance and is winding down.

Challenges and risks

Raw material cost and supply
Raw materials are about 75% of cost of sales; after the Middle East conflict 52 force majeures remained in place in Q2 fiscal 2026 and the CEO does not expect a rapid recovery of global supply chains.
Falling volumes
Q3 fiscal 2026 volume fell 3.0%; small and mid-sized customers are spacing out orders, and HHC volumes are hurt by GLP-1 drugs and low household formation.
Shareholder activism
Ancora Holdings Group's rejected proposal for BAS and its threatened public campaign are a new risk factor; separating BAS would bring dis-synergies because it shares plants and solvent purchasing with other units.
Leverage and working capital
Total debt was $2,054.5 million at Q3 fiscal 2026, inventory days rose to 88 from 78, and nine-month free cash flow was $40.9 million.
Litigation and regulation
The Rouse grout case is set to settle for up to $75.0 million; PFAS regulation and OECD Pillar Two are named regulatory risks.

What leadership says

“deleveraging will be a very, very high priority for us”

Celeste Mastin, President and Chief Executive Officer · Q3 2026 earnings call, September 24, 2026

“the possibility that we will divest something is something we're taking very seriously”

Celeste Mastin, President and Chief Executive Officer · Q3 2026 earnings call, September 24, 2026, on the annual portfolio review

“we do not expect a rapid recovery of global supply chains”

Celeste Mastin, President and Chief Executive Officer · Q2 2026 earnings call, June 25, 2026

“the second largest surgical tissue bonding company in the world”

Celeste Mastin, President and Chief Executive Officer · Q3 2026 earnings call, September 24, 2026, on the combination with AMS

Where a supplier can help

Plant consolidation and real estate
Quantum Leap closes about 20 plants by end-2026 and sells them; suppliers of manufacturing transfer, equipment relocation, automation and industrial real estate services fit this programme.
Raw material sourcing resilience
With raw materials at about 75% of cost of sales and supply still disrupted, alternative specialty chemical suppliers and sourcing analytics tied to the pricing and supply challenge are relevant.
Medical integration
Integrating AMS and the Peters Surgical consolidation, with $55 million of synergies targeted, needs regulatory, quality, cross-selling and integration support in medical devices.
Working capital and inventory
The CFO targets an inventory reduction of at least 5 days; inventory planning and supply chain tools address the rise in inventory days to 88.
ERP finish and AMS onboarding
Project ONE is winding down while AMS sites in the UK, Germany, France, Thailand and India join; system integration and data migration services map to that transition.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like H.B. Fuller?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about H.B. Fuller

What does H.B. Fuller do?

H.B. Fuller formulates, makes and sells adhesives, sealants and specialty chemicals for packaging, hygiene, medical, transportation, electronics, aerospace and construction customers, through three segments: HHC, Engineering Adhesives and Building Adhesive Solutions.

What is H.B. Fuller's revenue?

Net revenue was $3,473.6 million in fiscal 2025, with adjusted EBITDA of $620.7 million. In the first nine months of fiscal 2026 revenue was $2,659.3 million, up 3.1%.

How many employees does H.B. Fuller have?

About 7,100 employees in 44 countries as of November 29, 2025, about 2,500 of them in the U.S.

What is H.B. Fuller's strategy?

It aims for 5% constant-currency growth and a 20% EBITDA margin, is adding a medical segment through the AMS acquisition, and is consolidating plants under Quantum Leap while reviewing its portfolio.

Who leads H.B. Fuller?

Celeste B. Mastin has been President and CEO since December 2022; John J. Corkrean is EVP and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)